The Experts below are selected from a list of 225 Experts worldwide ranked by ideXlab platform
Kathleen L. Hefferon - One of the best experts on this subject based on the ideXlab platform.
-
Plant Virus Expression Vectors: A Powerhouse for Global Health.
Biomedicines, 2017Co-Authors: Kathleen L. HefferonAbstract:Plant-made biopharmaceuticals have long been considered a promising technology for providing inexpensive and efficacious medicines for developing countries, as well as for combating pandemic infectious diseases and for use in personalized medicine. Plant Virus Expression vectors produce high levels of pharmaceutical proteins within a very short time period. Recently, plant Viruses have been employed as nanoparticles for novel forms of cancer treatment. This review provides a glimpse into the development of plant Virus Expression systems both for pharmaceutical production as well as for immunotherapy.
-
DNA Virus Vectors for Vaccine Production in Plants: Spotlight on GeminiViruses.
Vaccine, 2014Co-Authors: Kathleen L. HefferonAbstract:Plants represent a safe, efficacious and inexpensive production platform by which to provide vaccines and other therapeutic proteins to the world’s poor. Plant Virus Expression vector technology has rapidly become one of the most popular methods to express pharmaceutical proteins in plants. This review discusses several of the state-of-the-art plant Expression systems based upon geminiViruses that have been engineered for vaccine production. An overview of the advantages of these small, single-stranded DNA Viruses is provided and comparisons are made with other Virus Expression systems. Advances in the design of several different geminiVirus vectors are presented in this review, and examples of vaccines and other biologics generated from each are described.
-
Virus Expression vectors.
Pharmaceutical patent analyst, 2014Co-Authors: Kathleen L. HefferonAbstract:For many years now, Virus Expression vectors have been explored as a mechanism for gene delivery, cancer therapy and vaccine development. More recently, the next generation of Virus vectors have been generated that possess greater attributes such as tissue specificity and improved Expression levels, while at the same time lack many of the shortcomings of their predecessors, such as issues regarding immunogenicity and safety. This review article describes several of the recent patents that have been issued in the field of Virus Expression vector development. Innovations in both plant and animal Virus Expression vectors are covered. The review concludes with a discussion of future prospects of Virus Expression vectors as tools in medical research.
-
Plant Virus Expression vector development: new perspectives.
BioMed Research International, 2014Co-Authors: Kathleen L. HefferonAbstract:Plant made biologics have elicited much attention over recent years for their potential in assisting those in developing countries who have poor access to modern medicine. Additional applications such as the stockpiling of vaccines against pandemic infectious diseases or potential biological warfare agents are also under investigation. Plant Virus Expression vectors represent a technology that enables high levels of pharmaceutical proteins to be produced in a very short period of time. Recent advances in research and development have brought about the generation of superior Virus Expression systems which can be readily delivered to the host plant in a manner that is both efficient and cost effective. This review presents recent innovations in plant Virus Expression systems and their uses for producing biologics from plants.
Sondra Schlesinger - One of the best experts on this subject based on the ideXlab platform.
-
sindbis Virus Expression vectors packaging of rna replicons by using defective helper rnas
Journal of Virology, 1993Co-Authors: P J Bredenbeek, Ilya Frolov, Charles M Rice, Sondra SchlesingerAbstract:: Since the recovery of infectious RNA transcripts from full-length cDNA clones, alphaVirus genome RNAs have been engineered to allow Expression of heterologous RNAs and proteins. The highest levels of Expression of heterologous products are achieved when the viral structural genes are replaced by the heterologous coding sequences. Such recombinant RNAs are self-replicating (replicons) and can be introduced into cells as naked RNA, but they require trans complementation to be packaged and released from cells as infectious virion particles. In this report, we describe a series of defective Sindbis Virus helper RNAs which can be used for packaging Sindbis Virus RNA replicons. The defective helper RNAs contain the cis-acting sequences required for replication as well as the subgenomic RNA promoter which drives Expression of the structural protein genes. In cells cotransfected with both the replicon and defective helper RNAs, viral nonstructural proteins translated from the replicon RNA allow replication and transcription of the defective helper RNA to produce the virion structural proteins. A series of defective helper RNAs were compared for the ability to package the replicon RNA as well as for the ability to be replicated and packaged. One defective helper RNA not only packaged the replicon but also was itself encapsidated and would be useful under conditions in which extensive amplification is advantageous. Other defective helper RNAs were able to package the replicon efficiently but were packaged very poorly themselves. These helpers should be useful for applications in which Expression of the viral structural proteins or Virus spread is not desired.
Patricia L Earl - One of the best experts on this subject based on the ideXlab platform.
-
Overview of the vaccinia Virus Expression system.
Current protocols in molecular biology, 2020Co-Authors: Bernard Moss, Patricia L EarlAbstract:The vaccinia Virus Expression system differs from others in that transcription occurs in the cytoplasm of mammalian cells rather than in the nucleus. As a vector, vaccinia Virus has a number of useful characteristics, including a capacity that permits cloning large fragments of foreign DNA (20+ kbp) with retention of infectivity, a wide host range, a relatively high level of protein synthesis, and "appropriate" transport, secretion, processing, and posttranslational modifications as dictated by the primary structure of the expressed protein and the cell type used. This overview discusses the life cycle of the vaccinia Virus along with effects of vaccinia infection. The vaccinia vector Expression system is described along with specific steps for expressing genes using these vectors. Important safety considerations are also presented.
-
Current Protocols in Molecular Biology - Overview of the Vaccinia Virus Expression System
Current protocols in protein science, 2020Co-Authors: Bernard Moss, Patricia L EarlAbstract:: The vaccinia Virus Expression system differs from others in that transcription occurs in the cytoplasm of mammalian cells rather than in the nucleus. As a vector, vaccinia Virus has a number of useful characteristics, including a capacity that permits cloning large fragments of foreign DNA (20+ kbp) with retention of infectivity, a wide host range, a relatively high level of protein synthesis, and "appropriate" transport, secretion, processing, and posttranslational modifications as dictated by the primary structure of the expressed protein and the cell type used. This overview discusses the life cycle of the vaccinia Virus along with effects of vaccinia infection. The vaccinia vector Expression system is described along with specific steps for expressing genes using these vectors. Important safety considerations are also presented.
-
UNIT 16.15 Overview of the Vaccinia Virus Expression System
Current protocols in protein science, 1998Co-Authors: Bernard Moss, Patricia L EarlAbstract:The vaccinia Virus Expression system differs from others in that transcription occurs in the cytoplasm of mammalian cells rather than in the nucleus. As a vector, vaccinia Virus has a number of useful characteristics, including a capacity that permits cloning large fragments of foreign DNA (20+ kbp) with retention of infectivity, a wide host range, a relatively high level of protein synthesis, and “appropriate” transport, secretion, processing, and posttranslational modifications as dictated by the primary structure of the expressed protein and the cell type used. This overview discusses the life cycle of the vaccinia Virus along with effects of vaccinia infection. The vaccinia vector Expression system is described along with specific steps for expressing genes using these vectors. Important safety considerations are also presented.
Kathleen Hefferon - One of the best experts on this subject based on the ideXlab platform.
-
plant Virus Expression vectors set the stage as production platforms for biopharmaceutical proteins
Virology, 2012Co-Authors: Kathleen HefferonAbstract:Transgenic plants present enormous potential as a cost-effective and safe platform for large-scale production of vaccines and other therapeutic proteins. A number of different technologies are under development for the production of pharmaceutical proteins from plant tissues. One method used to express high levels of protein in plants involves the employment of plant Virus Expression vectors. Plant Virus vectors have been designed to carry vaccine epitopes as well as full therapeutic proteins such as monoclonal antibodies in plant tissue both safely and effectively. Biopharmaceuticals such as these offer enormous potential on many levels, from providing relief to those who have little access to modern medicine, to playing an active role in the battle against cancer. This review describes the current design and status of plant Virus Expression vectors used as production platforms for biopharmaceutical proteins.
-
Recent Advances in Virus Expression Vector Strategies for VaccineProduction in Plants
Virology & Mycology, 2012Co-Authors: Kathleen HefferonAbstract:Plants offer tremendous advantages as cost-effective and safe platforms for the large-scale production of vaccines and other therapeutic proteins. Plant-derived vaccines represent a means by which to enhance vaccine coverage for children in developing countries, and can be administered orally to elicit a mucosal immune response. Plantderived vaccines possess the dual advantage of preventing the antigen from degradation as it passes through the gastrointestinal tract, while at the same time being capable of delivering an antigen to the mucosal immune system. Plant Virus vectors have been designed to express vaccine epitopes as well as full therapeutic proteins in plant tissue. This review describes recent advances with respect to plant Virus Expression vectors used as production platforms for biopharmaceutical proteins.
Yosef Shaul - One of the best experts on this subject based on the ideXlab platform.
-
inhibition of hepatitis b Virus Expression and replication by rna interference
Hepatology, 2003Co-Authors: Amir Shlomai, Yosef ShaulAbstract:RNA interference (RNAi) is the process of sequence-specific gene silencing, initiated by double-stranded RNA (dsRNA) that is homologous in sequence to the target gene. Because it has been shown that RNAi can be accomplished in cultured mammalian cells by introducing small interfering RNAs (siRNAs), much effort has been invested in exploiting this phenomenon for experimental and therapeutic means. In this study, we present a series of experiments showing a significant reduction in hepatitis B Virus (HBV) transcripts and proteins in cell culture, as well as in the viral replicative forms, induced by siRNA-producing vectors. The antiviral effect is sequence-specific and does not depend on active viral replication. In conclusion, our data suggest that RNAi may provide a powerful therapeutic tool, acting both on replication-competent and on replication-incompetent HBV. (Hepatology 2003;37:764-770.)
